Sanofi India Limited has informed the Exchange about transcript of Investor/Analysts call held on 29th October 2025.
SANOFI · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Sanofi India held an investor call to discuss Q3 FY26 (quarter ended 30 Sept 2025) results, highlighting its business transformation focused on diabetes and insulin. Revenue from operations grew ~4% YTD and ~5% YoY in the quarter, with the partnership model (legacy cardio, CNS, oral anti-diabetes) delivering 2% YTD and 5% QoQ growth. Exports dropped sharply due to a 2020 divestment of the Ankleshwar site to Zentiva, partially offset by new markets like Russia and South Africa. OPEX fell ~30% versus the prior quarter, improving the cost-to-sales ratio to 22% and lifting PBT margin from 23% to 29%. The Board declared an interim dividend of INR 75 per share. No new product launches are planned for 2026, with focus on scaling Toujeo and Soliqua, and AI is being deployed across R&D, sales, and finance.
Margin expansion driven by OPEX discipline and a focused diabetes strategy is positive for profitability, while the dividend of INR 75/share rewards shareholders. However, the near-term top line remains pressured by export weakness and lower-margin partnership economics, and absence of new launches in 2026 may limit growth visibility.